Devyser Diagnostics AB (OSTO:DVYSR) ROCE % : -9.10% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Devyser Diagnostics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Devyser Diagnostics AB's annualized ROCE % for the quarter that ended in Mar. 2024 was -9.10%.

Devyser Diagnostics AB ROCE % Historical Data

The historical data trend for Devyser Diagnostics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devyser Diagnostics AB ROCE % Chart

Devyser Diagnostics AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

21.64

-21.07

-8.85

-11.91

-11.96

Devyser Diagnostics AB Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial												-17.38	-11.98	-3.99	-14.21	-9.10

Devyser Diagnostics AB ROCE % Calculation

Devyser Diagnostics AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-53.6	/	( ( (500.6 - 51.2)	+	(510.1 - 62.9) )	/ 2 )
	=	-53.6	/	( (449.4	+	447.2)	/ 2 )
	=	-53.6	/	448.3
	=	-11.96 %

Devyser Diagnostics AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-40	/	( ( (510.1 - 62.9)	+	(496.6 - 64.9) )	/ 2 )
	=	-40	/	( ( 447.2	+	431.7 )	/ 2 )
	=	-40	/	439.45
	=	-9.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Devyser Diagnostics AB (OSTO:DVYSR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Devyser Diagnostics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Devyser Diagnostics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Devyser Diagnostics AB (OSTO:DVYSR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Devyser Diagnostics AB (OSTO:DVYSR) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Instrumentvagen 19, Hagersten, SWE, 126 53

Website

https://www.devyser.com

Devyser Diagnostics AB is specialized in the development, manufacture and sale of market-leading genetic diagnostic kits.The products are used for complex DNA testing in the hereditary disease, oncology and post-transplantation monitoring fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up.

Devyser Diagnostics AB (OSTO:DVYSR) Headlines

No Headlines